Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.
Latest website image capture
Clouds background image

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page

  1. Check
    3 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0 on a page displaying a 403 error.
    Difference
    0.2%
    Check dated 2026-11-01T13:25:52.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A site-wide notice announces that NIH is transitioning to the term “Super Intelligence” in place of “Artificial Intelligence” and links to transition updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T13:24:08.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2. The page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-18T13:34:32.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer revision number changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T13:38:49.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study record content with a standard error page and site chrome, indicating the study details are not accessible at this URL.
    Difference
    18%
    Check dated 2026-09-20T19:55:27.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6. This represents a small administrative update to the study record and does not affect trial details or visible content.
    Difference
    0.1%
    Check dated 2026-08-30T16:50:37.000Z thumbnail image

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.